 |
|
Assessing the Preferences of Patients With PsoriasisA Quantitative, Utility Approach
Kathryn A. Zug, MD;
Benjamin Littenberg, MD;
Richard D. Baughman, MD;
Terry Kneeland, MPH;
Robert F. Nease, PhD;
Walt Sumner, MD;
Gerald T. O'Connor, PhD;
Rebecca Jones, MD;
Elizabeth Morrison, MD;
Robert Cimis, MD
Arch Dermatol. 1995;131(5):561-568.
Abstract
| |
Background and Design
Patient preferences for health outcomes can be explicitly assessed and expressed in quantitative terms known as utilities. Three standard methods for utility assessment have been used to quantify patient preferences, but these methods have not previously been applied to skin disease. Eighty-seven patients with psoriasis from a tertiary medical center were interviewed, using an interactive, computer-based utility assessment questionnaire, U-Titer. Utilities for three categories of psoriasis severity and potential adverse outcomes of methotrexate therapy were assessed by the vertical rating scale, time trade-off, and standard gamble.
Results
Patients assigned a broad range of utilities for each of the health states. Utilities obtained by the vertical rating scale did not correlate well with utilities obtained by standard gamble or time trade-off methods. However, utilities assessed by standard gamble and time trade-off were not significantly different. Patient characteristics such as age, gender, and education were not correlated with utility and did not explain the variation. Indicators of the patients' disease severity were not predictive of utilities for the assessed health states. The relatively high utility for liver biopsy suggests that there is less patient aversion to the procedure than suspected.
Conclusions
Utilities, or quantitative measures of patient preferences for health states, are measurable and vary widely for mild, moderate, and severe psoriasis and possible adverse outcomes of methotrexate treatment. The process of elucidating individual patient utilities for various health outcomes can be used to incorporate patient preferences into the process of clinical decision making. Guidelines that are based solely on severity of symptoms, without input from patients on how they value such symptoms, must be questioned.
(Arch Dermatol. 1995;131:561-568)
Author Affiliations
From the Department of Medicine, Sections of Dermatology (Drs Zug, Baughman, Jones, and Morrison), Clinical Research (Drs Littenberg, O'Connor, and Kneeland), and Gastroenterology (Dr Cimis), and the Department of Community and Family Medicine, Center for Evaluative Clinical Sciences (Drs Nease and Sumner), Dartmouth-Hitchcock Medical Center, Lebanon, NH. Currently, Dr Zug is with Emory University Department of Dermatology, Atlanta, Ga; Drs Littenberg and Nease are with the Program in General Medical Sciences, Washington University, St Louis, Mo; Dr Sumner is with the Department of Family Practice, University of Kentucky Medical Center, Lexington; and Dr Morrison is an intern in the Department of Medicine, Beth Israel Hospital, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Health Utility Bias: A Systematic Review and Meta-Analytic Evaluation
Doctor et al.
Med Decis Making 2010;30:58-67.
ABSTRACT
Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review
McLernon et al.
Med Decis Making 2008;28:582-592.
ABSTRACT
iMPACT3: Internet-Based Development and Administration of Utility Elicitation Protocols
Lenert et al.
Med Decis Making 2002;22:464-474.
ABSTRACT
Psoriasis From the Patient's Point of View
Finlay
Arch Dermatol 2001;137:352-353.
FULL TEXT
Parents' Utilities for Outcomes of Occult Bacteremia
Bennett et al.
Arch Pediatr Adolesc Med 2000;154:43-48.
ABSTRACT
| FULL TEXT
The Development of Practice Guidelines for the Treatment of Severe Plaque Form Psoriasis
Spuls et al.
Arch Dermatol 1998;134:1591-1596.
ABSTRACT
| FULL TEXT
Cost-effectiveness and Cost-Benefit Analysis of Using Methotrexate vs Goeckerman Therapy for Psoriasis: A Pilot Study
Chen et al.
Arch Dermatol 1998;134:1602-1608.
ABSTRACT
| FULL TEXT
Reliability Testing of the Dermatology Index of Disease Severity (DIDS) An Index for Staging the Severity of Cutaneous Inflammatory Disease
Faust et al.
Arch Dermatol 1997;133:1443-1448.
ABSTRACT
A 61-Year-Old Man With Psoriasis
Baughman
JAMA 1996;276:1421-1428.
ABSTRACT
|
